Article Top Ad


Versameb AG, a preclinical stage company focused on the discovery and development of innovative RNA-based therapeutics, today announced that its Chief Scientific Officer, Friedrich Metzger, will present at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2022 Winter Meeting, to be held 22. 26 February 2022 in San Diego, California, will present data on the mRNA engineering technology and the company’s lead therapeutic candidate, VMB-100.

Versameb has developed a breakthrough proprietary technology platform that optimizes the application of functional RNA in multiple disease contexts. The lead therapeutic candidate, VMB-100, has demonstrated first-in-class potential for the treatment of stress urinary incontinence (SUI) in a preclinical animal model demonstrating regeneration and functional restoration of the urinary sphincter.

Friedrich Metzger, Chief Scientific Officer, said: “Our findings demonstrate a single local injection of our engineered mRNA results in therapeutically relevant target protein expression and secretion in the affected muscle tissue leading to tissue regeneration. These findings support the therapeutic potential of this treatment for Stress Urinary Incontinence as well as other muscle-related disorders, by restoring muscle functionality.”

Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting
Date: 22-26 February 2022San Diego, California. In-person
Presentation by: Friedrich Metzger
Title: Regeneration of Muscle Tissue and Function In Stress Urinary Incontinence Using Engineered RNA, #NM20
Authors: Justin Antony SelvarajClaudia BohnertPascale BirrerSina ZimmerliIsabelle KappelerTatsuo SatohPetra HillmannIsabel Ferreira, Klaas Zuideveld, Friedrich Metzger, Versameb AG
Date & Time: 24 February, 13.00pm EST

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting at the prestigious SUFU 2022 Winter Meeting. Our next-generation mRNA technology offers a pioneering potential treatment for Stress Urinary Incontinence through tissue regeneration. As a team, we remain committed and are working towards technology that will allow the rejuvenation of the urinary sphincter and address the unmet medical need of patients. Currently, up to 50% of adult women worldwide suffer from SUI with no drug treatment approved for restoration”.

For more information, please visit them at